Ideal Steroids for Asthma Treatment in the PICU
NCT03900624
Completed
Determine if differences in (1) pediatric intensive care unit length of stay, (2) continuous nebulized albuterol duration, and (3) a composite outcome of advanced asthma therapy incidence including use of non-invasive ventilation (NIV), terbutaline, inhaled helium and mechanical ventilation between cohorts of children admitted with status asthmaticus to the PICU treated with either IV dexamethasone (DM) or methylprednisolone (MP).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
02/19/2024
Locations: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Conditions: Asthma Childhood
Register for Updates
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
NCT05288062
Active Not Recruiting
This phase II trial studies the effect of immunomodulatory drug(s) in combination with a corticosteroid drug in treating patients with multiple myeloma or smoldering multiple myeloma. Immunomodulatory drugs such as lenalidomide and pomalidomide work through a variety of mechanisms to affect the function of the immune system. They are widely used as treatment for multiple myeloma and remain the backbone of therapy for both newly diagnosed patients and patients that have multiple myeloma that has... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +3 locations
Conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Register for Updates
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
NCT04329728
Recruiting
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Gender:
ALL
Ages:
Between 12 years and 95 years
Trial Updated:
02/13/2024
Locations: City of Hope, Duarte, California +10 locations
Conditions: Lymphoid Malignancies
Register for Updates
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
NCT03435003
Completed
Bariatric surgery remains the most effective therapy for obesity. Postoperative nausea and vomiting (PONV) are commonly reported following bariatric surgery. The proposed study focuses on the most common bariatric procedure performed, laparoscopic sleeve gastrectomy (LSG), and aims to assess the effect of a post-operative nausea and vomiting-specific intervention. The investigators hypothesize that the intervention group will experience a reduction of nausea-related prolonged hospital stay and s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Stony Brook University Hospital, Stony Brook, New York
Conditions: Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy
Register for Updates
Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
NCT05697809
Active Not Recruiting
The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis® illuminated microcatheterization device compared with intravitreal dexamethasone implant (OZURDEX®) in subjects with diabetic macular edema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Retinal Research Institute, LLC, Phoenix, Arizona +8 locations
Conditions: Diabetic Macular Edema
Register for Updates
Iontophoresis With Dexamethasone and Physical Therapy to Treat Apophysitis of the Knee in Pediatrics
NCT03606980
Terminated
The goal of this clinical research study is to determine if there is a difference in time to meet return to sport criteria for Pediatric patients with apophysitis of the knee who receive iontophoresis with Dexamethasone Sodium Phosphate (DSP) and Physical Therapy (PT) as those who receive iontophoresis with placebo and PT or PT alone. Approximately 147 patients will be enrolled in this study.
Gender:
ALL
Ages:
Between 7 years and 18 years
Trial Updated:
02/07/2024
Locations: CHKD Sports Medicine Physical Therapy - Oakbrooke, Chesapeake, Virginia +4 locations
Conditions: Apophysitis; Juvenile
Register for Updates
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
NCT04912427
Terminated
This is a phase Ib study to assess the safety, tolerability, preliminary efficacy, and renal response of isatuximab, bortezomib, and dexamethasone in newly diagnosed multiple myeloma patients with severe renal impairment or dialysis-dependent end-stage renal disease. Such patients have limited therapeutic options due to renal clearance or nephrotoxicity of many myeloma therapies and are often excluded from clinical trials. Isatuximab in other regimens has shown efficacy and tolerability in patie... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Multiple Myeloma
Register for Updates
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01527149
Completed
This phase II trial studies how well ofatumumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and dexamethasone alternating with ofatumumab in combination with cytarabine and methotrexate works in treating patients with newly diagnosed mantle cell lymphoma (MCL). Monoclonal antibodies, such as ofatumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincr... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/04/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York +1 locations
Conditions: Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
Register for Updates
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
NCT04009109
Active Not Recruiting
A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and daratumumab. Patients will be randomized to either: Arm A: 12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/02/2024
Locations: Northern Light Eastern Maine Medical Center, Bangor, Maine +6 locations
Conditions: Myeloma, Multiple
Register for Updates
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
NCT05922501
Not Yet Recruiting
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
Register for Updates
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
NCT03151811
Terminated
This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with RRMM following 2-4 lines of prior therapy and who were refractory to lenalidomide in the last line of therapy as demonstrated by disease progression on or within 60 days of completion of the last dose of lenalidomide. Patients received either melflufen+dex or pomalidomide+dex.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: US17, Tucson, Arizona +104 locations
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone for Post Uterine Artery Embolization Pain
NCT04655144
Active Not Recruiting
The purpose of this research is to investigate if administration steroids (anti-inflammatory medication) via the uterine arteries during uterine fibroid embolization (A non surgical procedure for treating uterine fibroids by blocking their blood supply) can help reduce the pain, nausea, vomiting, and general feeling of weakness following the procedure.
Gender:
FEMALE
Ages:
Between 20 years and 50 years
Trial Updated:
01/29/2024
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Leiomyoma
Register for Updates